RCKT Valuation

Rocket Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

3.280

-0.07(-2.090%)1D

Overview
Forecast
Valuation
Earnings

RCKT Relative Valuation

RCKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCKT is overvalued; if below, it's undervalued.

Historical Valuation

Rocket Pharmaceuticals Inc (RCKT) is now in the Fair zone, suggesting that its current forward PS ratio of 502.82 is considered Fairly compared with the five-year average of -8.21. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.28

Fair

-2.00

Trailing

Forward

-0.55

EV/EBITDA

Rocket Pharmaceuticals Inc. (RCKT) has a current EV/EBITDA of -0.55. The 5-year average EV/EBITDA is -7.28. The thresholds are as follows: Strongly Undervalued below -17.76, Undervalued between -17.76 and -12.52, Fairly Valued between -2.05 and -12.52, Overvalued between -2.05 and 3.19, and Strongly Overvalued above 3.19. The current Forward EV/EBITDA of -0.55 falls within the Overvalued range.

-0.53

EV/EBIT

Rocket Pharmaceuticals Inc. (RCKT) has a current EV/EBIT of -0.53. The 5-year average EV/EBIT is -6.40. The thresholds are as follows: Strongly Undervalued below -15.93, Undervalued between -15.93 and -11.16, Fairly Valued between -1.63 and -11.16, Overvalued between -1.63 and 3.13, and Strongly Overvalued above 3.13. The current Forward EV/EBIT of -0.53 falls within the Overvalued range.

502.82

Rocket Pharmaceuticals Inc. (RCKT) has a current PS of 502.82. The 5-year average PS is 731.93. The thresholds are as follows: Strongly Undervalued below -4138.42, Undervalued between -4138.42 and -1703.25, Fairly Valued between 3167.10 and -1703.25, Overvalued between 3167.10 and 5602.27, and Strongly Overvalued above 5602.27. The current Forward PS of 502.82 falls within the Historic Trend Line -Fairly Valued range.

-5.69

P/OCF

Rocket Pharmaceuticals Inc. (RCKT) has a current P/OCF of -5.69. The 5-year average P/OCF is -10.28. The thresholds are as follows: Strongly Undervalued below -22.20, Undervalued between -22.20 and -16.24, Fairly Valued between -4.32 and -16.24, Overvalued between -4.32 and 1.64, and Strongly Overvalued above 1.64. The current Forward P/OCF of -5.69 falls within the Historic Trend Line -Fairly Valued range.

-2.53

P/FCF

Rocket Pharmaceuticals Inc. (RCKT) has a current P/FCF of -2.53. The 5-year average P/FCF is -9.71. The thresholds are as follows: Strongly Undervalued below -22.15, Undervalued between -22.15 and -15.93, Fairly Valued between -3.49 and -15.93, Overvalued between -3.49 and 2.73, and Strongly Overvalued above 2.73. The current Forward P/FCF of -2.53 falls within the Overvalued range.

Rocket Pharmaceuticals Inc (RCKT) has a current Price-to-Book (P/B) ratio of 1.02. Compared to its 3-year average P/B ratio of 3.47 , the current P/B ratio is approximately -70.60% higher. Relative to its 5-year average P/B ratio of 3.92, the current P/B ratio is about -73.98% higher. Rocket Pharmaceuticals Inc (RCKT) has a Forward Free Cash Flow (FCF) yield of approximately -57.02%. Compared to its 3-year average FCF yield of -18.16%, the current FCF yield is approximately 214.03% lower. Relative to its 5-year average FCF yield of -14.16% , the current FCF yield is about 302.72% lower.

1.02

P/B

Median3y

3.47

Median5y

3.92

-57.02

FCF Yield

Median3y

-18.16

Median5y

-14.16

Competitors Valuation Multiple

The average P/S ratio for RCKT's competitors is 102.44, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT) exhibits a P/S ratio of 502.82, which is 390.85% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RCKT.O

Rocket Pharmaceuticals Inc

Bright Minds Biosciences Inc

Loss

275.49M

INBX.O

Inhibrx Biosciences Inc

Loss

1200.00%

408.22M

Performance Decomposition

Market capitalization of RCKT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of RCKT in the past 1 year is driven by Unknown.